Brief: Iovance Biotherapeutics Says FDA Has Lifted Clinical Hold On The Iov-Lun-202 Registrational Trial
04/03/2024 11:32
March 4 (Reuters) - Iovance Biotherapeutics Inc
IOVA.O :
* IOVANCE BIOTHERAPEUTICS ANNOUNCES FDA HAS LIFTED CLINICAL
HOLD
ON THE IOV-LUN-202 REGISTRATIONAL TRIAL IN NON-SMALL CELL LUNG
CANCER
* IOVANCE BIOTHERAPEUTICS INC - UPON REVIEWING THIS
PROPOSAL, FDA
HAS CLEARED IOVANCE TO RESUME PATIENT ENROLLMENT IN IOV-LUN-202
* IOVANCE BIOTHERAPEUTICS INC - EXPECTS TO COMPLETE
ENROLLMENT OF
APPROXIMATELY 120 PATIENTS IN IOV-LUN-202 REGISTRATIONAL COHORTS
IN 2025
Source text for Eikon: ID:nGNXbRK5D0
Further company coverage: IOVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies